%0 Journal Article
%A Flaadt, Tim
%A Ebinger, Martin
%A Schreiber, Malin
%A Ladenstein, Ruth L
%A Simon, Thorsten
%A Lode, Holger N
%A Hero, Barbara
%A Schuhmann, Martin U
%A Schäfer, Jürgen
%A Paulsen, Frank
%A Timmermann, Beate
%A Eggert, Angelika
%A Lang, Peter
%T Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System Relapse.
%J Journal of Clinical Medicine
%V 12
%N 19
%@ 2077-0383
%C Basel
%I MDPI
%M DKFZ-2023-02067
%P 6196
%D 2023
%X Despite highly intensive multimodality treatment regimens, the prognosis of patients with high-risk neuroblastoma (HRNB) and central nervous system (CNS) relapse remains poor. We retrospectively reviewed data from 13 patients with HRNB and CNS relapse who received multimodal therapy with consolidating haploidentical stem cell transplantation (haplo-SCT) followed by dinutuximab beta ± subcutaneous interleukin-2 (scIL-2). Following individual relapse treatment, patients aged 1-21 years underwent haplo-SCT with T/B-cell-depleted grafts followed by dinutuximab beta 20 mg/m2/day × 5 days for 5-6 cycles. If a response was demonstrated after cycle 5 or 6, patients received up to nine treatment cycles. After haplo-SCT, eight patients had a complete response, four had a partial response, and one had a stable disease. All 13 patients received ≥3 cycles of immunotherapy. At the end of the follow-up, 9/13 patients (66.7
%K central nervous system (Other)
%K dinutuximab beta (Other)
%K neuroblastoma (Other)
%K recurrence (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37834840
%2 pmc:PMC10573405
%R 10.3390/jcm12196196
%U https://inrepo02.dkfz.de/record/284756